Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results
CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results


There was an inadvertent error on the supplementary table titled “Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare

EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis   : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: Changes on the Board of Management: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: Changes on the Board of Management
EQS-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: Changes on the Board of Management
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
Henry Ford Health and Acadia Healthcare Break Ground on New Behavioral Health Hospital: https://mms.businesswire.com/media/20220927006047/en/1584747/5/AcadiaHealthcareHenryFordHealthGroundbreaking.jpg
Henry Ford Health and Acadia Healthcare Break Ground on New Behavioral Health Hospital


Henry Ford Health, one of the nation’s premier academic and integrated health systems, and Acadia Healthcare, the nation’s largest stand-alone behavioral healthcare company, broke ground today on a

EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
Acadia Healthcare Appoints Dr. Nasser Khan to Lead Its CTC Business: https://mms.businesswire.com/media/20220914005293/en/1571136/5/Kahn_photo.jpg
Acadia Healthcare Appoints Dr. Nasser Khan to Lead Its CTC Business


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the appointment of Dr. Nasser Khan, M.D., as Operations Group President for its Comprehensive Treatment Center (CTC) business. Dr

DGAP-News: Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
DGAP-News: Gerresheimer AG: Gerresheimer AG and Stevanato Group announce Collaboration on the Development of an innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-News: Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
DGAP-Adhoc: GN Store Nord A/S: GN Interim Report Q2 2022: https://mms.businesswire.com/media/20220816005068/en/1543852/5/GN_Logo_RGB_300ppi.jpg
DGAP-Adhoc: GN Store Nord A/S: GN Interim Report Q2 2022
DGAP-Adhoc: GN Store Nord A/S: GN Interim Report Q2 2022
DGAP-News: Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source
DGAP-News: Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source
GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise: https://mms.businesswire.com/media/20220816005068/en/1543855/5/RS_OMNIA_birthday_cleaning_talk_RIE_1114.jpg
GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise


GN Hearing, the global leader in hearing aid innovation, today announces the launch of ReSound OMNIA – a new hearing aid platform that will set a new standard in hearing technology and improve how

DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
Gerresheimer AG: Gerresheimer invests up to 94 million Dollar in US production facility : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer invests up to 94 million Dollar in US production facility
Gerresheimer AG: Gerresheimer invests up to 94 million Dollar in US production facility
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022